Bromocriptine Therapy in Multiple SclerosisAn Open Label Pilot Study
作者:
Véronique Bissay,
Nina Klippel,
Luc Herroelen,
Eric Schmedding,
Therèse Buisseret,
Guy Ebinger,
Jacques Keyser,
期刊:
Clinical Neuropharmacology
(OVID Available online 1994)
卷期:
Volume 17,
issue 5
页码: 473-476
ISSN:0362-5664
年代: 1994
出版商: OVID
关键词: Multiple sclerosis;Bromocriptine;Prolactin
数据来源: OVID
摘要:
SummaryBromocriptine suppresses the duration and severity of clinical signs of experimental allergic encephalitis, which is considered as an animal model for multiple sclerosis (MS). We conducted an open pilot study with 2.5 mg of bromocriptine two times a day on 18 patients with clinically or laboratory-supported definite MS (10 with the relapsing-remitting form and eight with the chronic progressive form). After 1 year of treatment, 14 of the 15 patients who completed the study showed disease progression as evidenced by one or more of the following parameters: worsening of the EDSS score, clinical relapses, appearance of new lesions on MRI of the brain and brainstem, or increased latencies of visual or auditory evoked responses. These findings indicate that bromocriptine does not completely suppresses ongoing disease activity in patients with multiple sclerosis.
点击下载:
PDF
(194KB)
返 回